
Nuntius Therapeutics
Cell-specific genetic medicines
- Location
- London, United Kingdom
- Team size
- 2 employees
- YC batch
- Winter 2021
- Status
- Active
- Stage
- Early stage

Cell-specific genetic medicines

What they do:
Delivering RNA therapies.
Quick facts:
HQ: London, United Kingdom

What they do:
mRNA therapeutics to extend healthspan entering clinical trials
Quick facts:
HQ: San Francisco, CA, United States

What they do:
Programmable DNA drug destroying all cancers, unlocking 80% of targets
Quick facts:
HQ: Oxford, United Kingdom

What they do:
Unleash the potential of genomic medicine using AI
Quick facts:
Funding:
€23.2M · Series B · Oct 2026

What they do:
Enabling next generation medicines. A comprehensive platform and…
Quick facts:
HQ: San Francisco, CA, United States

What they do:
Empowering Mass Spec for Biotech and Beyond
Quick facts:
HQ: Atlanta, GA, United States
Cell-specific genetic medicines
London, United Kingdom
2 employees, according to the company profile.
There are no funding rounds for Nuntius Therapeutics in our data.
Similar startups: Sixfold Bioscience, Rejuvenation Technologies Inc., and FinalDose.